Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming
International Journal of Molecular Sciences · 30.09.2025 · 26 (19) · 9554
DOI: 10.3390/ijms26199554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.09.2025. Verfasst von Giada Mandracci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Neoplasms, Immunity, Innate, Immunotherapy, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Overcoming immune resistance remains the critical barrier to durable immunotherapy responses. Tumors with non-inflamed, “cold” microenvironments exclude cytotoxic lymphocytes and evade checkpoint blockade. Innate nucleic acid-sensing pathways—including TLRs, RIG-I-like RNA sensors, and the cGAS–STING DNA-sensing axis—can recondition this hostile landscape by licensing dendritic cells, restoring antigen presentation, and recruiting effector T and NK cells. In this review, we synthesize mechanistic insights into how these receptors function across tumor and immune compartments and evaluate recent translational advances spanning small-molecule and nucleic acid agonists, engineered delivery systems, and clinical trials. We highlight challenges that have limited clinical impact, including pathway silencing, systemic toxicity, and lack of predictive biomarkers, while emphasizing emerging solutions such as tumor-intrinsic targeting, CAR-T/NK engineering, and biomarker-guided patient selection. By integrating innate activation into rational combination regimens, innate immune reprogramming offers a blueprint to convert resistant disease into one susceptible to durable immune control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine III, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
- TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany.
ORCID-Profile: Giada Mandracci, Nardine Soliman, Nadia El Khawanky
Zitieren
APA
Mandracci, G., Soliman, N., & El Khawanky, N. (2025). Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming. International Journal of Molecular Sciences, 26(19), 9554. https://doi.org/10.3390/ijms26199554
Vancouver
Mandracci G, Soliman N, El Khawanky N. Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming. International Journal of Molecular Sciences. 2025;26(19):9554. doi:10.3390/ijms26199554
BibTeX
@article{Mandracci2025,
author = {Mandracci, Giada and Soliman, Nardine and El Khawanky, Nadia},
title = {Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {19},
pages = {9554},
doi = {10.3390/ijms26199554}
}
EUVIMED